Skip to content
The Policy VaultThe Policy Vault

dupilumab — Blue Cross Blue Shield of Montana

chronic obstructive pulmonary disease (COPD)

Initial criteria

  • Diagnosis confirmed by spirometry with post-bronchodilator FEV1/FVC <0.7.
  • Airflow obstruction defined by post-bronchodilator FEV1 30–70% of predicted normal.
  • Eosinophilic phenotype confirmed by baseline blood eosinophil count ≥300 cells/µL.
  • Symptoms of chronic bronchitis (chronic productive cough) for at least 3 months within the past 12 months.
  • History of inadequately controlled COPD while on maintenance therapy demonstrated by ONE of: ≥2 moderate exacerbations requiring systemic corticosteroids in the past 12 months OR severe exacerbation requiring hospitalization/mechanical ventilation/ER or urgent care visit in the past 12 months.